FDA: AveXis manipulated potency data for Zolgensma

FDA said Tuesday that AveXis manipulated in vivo potency data for gene therapy Zolgensma and failed to report the issue to the agency, holding back the information while the agency was reviewing its BLA. The company’s alleged decision to stay mum on the issue at first could open it up for

Read the full 519 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE